NTV Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

NTV Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-7,450	Closed	-$247K	–	184
2017 Q2	$247K	Buy	+7,450	New	+$231K	0.08%	163
2016 Q4	–	Sell	-4,683	Closed	-$215K	–	159
2016 Q3	$215K	Buy	4,683 +600	+15%	+$31.3K	0.08%	153
2016 Q2	$205K	Buy	4,083 +300	+8%	+$16K	0.08%	155
2016 Q1	$202K	Hold	3,783	–	–	0.08%	157
2015 Q4	$248K	Hold	3,783	–	–	0.1%	151
2015 Q3	$213K	Hold	3,783	–	–	0.07%	195
2015 Q2	$223K	Hold	3,783	–	–	0.07%	198
2015 Q1	$235K	Sell	3,783 -1,000	-21%	-$58.1K	0.07%	195
2014 Q4	$275K	Hold	4,783	–	–	0.08%	178
2014 Q3	$257K	Buy	4,783 +33	+0.7%	+$1.75K	0.08%	177
2014 Q2	$248K	Hold	4,750	–	–	0.08%	179
2014 Q1	$250K	Buy	+4,750	New	+$220K	0.08%	177

Other funds holding TEVA

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

NTV Asset Management's TEVA Position: Q3 2017 in Review

NTV Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 7,450 shares — an estimated $247K sold.

NTV Asset Management first reported a position in TEVA in Q1 2014 and held it in 12 quarters. The position peaked at $275K in Q4 2014. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

NTV Asset Management reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
NTV Asset Management sold 7,450 Teva Pharmaceuticals shares in Q3 2017, an estimated $247K.
NTV Asset Management first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 12 quarters.
NTV Asset Management's Teva Pharmaceuticals position peaked at $275K in Q4 2014.
535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on NTV Asset Management's 13F filing for Q3 2017, filed 6 Nov 2017.